<DOC>
	<DOCNO>NCT00954642</DOCNO>
	<brief_summary>This Phase Ib , open-label , dose-escalation study MNRP1685A give intravenous ( IV ) infusion therapy locally advance metastatic solid tumor .</brief_summary>
	<brief_title>A Study MNRP1685A Combination With Bevacizumab With Without Paclitaxel Patients With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adequate hematologic end organ function Evaluable disease measurable disease per Response Evaluation Criteria In Solid Tumors ( RECIST ) Agreement use effective form contraception duration study Inclusion Criteria Unique Arm A : Histologically cytologically document , incurable , locally advanced , metastatic solid malignancy progress , fail respond , least one prior regimen Inclusion Criteria Unique Arm B : Histologically cytologically document , incurable , locally advanced , metastatic solid malignancy ; maximum two prior chemotherapy regimen allow Any anticancer therapy , include chemotherapy , hormonal therapy , radiotherapy , within 3 week 5 halflives ( systemic agent ) , whichever short , prior initiation study treatment follow exception : hormonal therapy gonadotropinreleasing hormone ( GnRH ) agonists antagonists prostate cancer ; herbal therapy &gt; 1 week prior Day 1 ; hormonereplacement therapy oral contraceptive ; palliative radiotherapy bone metastases &gt; 2 week prior Day 1 Any condition require fulldose anticoagulant , warfarin , heparin , thrombolytic , filter inferior vena cava Leptomeningeal disease manifestation current malignancy Active infection require IV antibiotic Active autoimmune disease control nonsteroidal antiinflammatory drug , inhale corticosteroid , equivalent ≤ 10 mg/day prednisone Bisphosphonate therapy symptomatic hypercalcemia Known clinically significant liver disease , include active viral , alcoholic , hepatitis , cirrhosis Known human immunodeficiency virus ( HIV ) infection Known primary CNS malignancy , untreated active CNS metastasis Pregnancy , lactation breast feed Inadequately control hypertension History hypertensive crisis hypertensive encephalopathy History myocardial infarction unstable angina within 6 month prior Day 1 New York Heart Association ( NYHA ) Class II great CHF History stroke transient ischemic attack ( TIA ) within 6 month prior Day 1 Significant vascular disease ( e.g. , aortic aneurysm require surgical repair recent peripheral arterial thrombosis ) within 6 month prior Day 1 History hemoptysis within 1 month prior Day 1 Evidence bleed diathesis significant coagulopathy absence stable therapeutic anticoagulation Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior Day 1 History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 6 month prior Day 1 Clinical sign symptoms gastrointestinal obstruction requirement parenteral hydration , parenteral nutrition , tube feed active gastrointestinal condition Evidence abdominal free air explain paracentesis recent surgical procedure Serious , nonhealing wound , active gastrointestinal ulcer , untreated bone fracture Intrathoracic lung carcinoma squamous cell histology Grade ≥ 2 sensory neuropathy Any disease , metabolic dysfunction , physical examination finding , clinical laboratory finding , investigator 's opinion , give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication Known hypersensitivity recombinant human antibody Exclusion Criterion Unique Arm B : Known significant hypersensitivity paclitaxel drug use vehicle cremophor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Solid Tumor</keyword>
	<keyword>Locally Advanced Solid Tumor</keyword>
	<keyword>Avastin</keyword>
</DOC>